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Abstract
Myocilin is an eye protein found in the trabecular extracellular matrix (TEM), within the anatomic region that controls fluid
flow. Variants of myocilin, localized to its olfactomedin (OLF) domain, have been linked to inherited forms of glaucoma, a
disease associated with elevated intraocular pressure. OLF domains have also been implicated in psychiatric diseases and
cancers by their involvement in signaling, neuronal growth, and development. However, molecular characterization of OLFs
has been hampered by challenges in recombinant expression, a hurdle we have recently overcome for the myocilin OLF
domain (myoc-OLF). Here, we report the first detailed solution biophysical characterization of myoc-OLF to gain insight into
its structure and function. Myoc-OLF is stable in the presence of glycosaminoglycans, as well as in a wide pH range in buffers
with functional groups reminiscent of such glycosaminoglycans. Circular dichroism (CD) reveals significant b-sheet and b-
turn secondary structure. Unexpectedly, the CD signature is reminiscent of a-chymotrypsin as well as another ocular protein
family, the bc-crystallins. At neutral pH, intrinsic tryptophan fluorescence and CD melts indicate a highly cooperative
transition with a melting temperature of ,55uC. Limited proteolysis combined with mass spectrometry reveals that the
compact core structural domain of OLF consists of approximately residues 238-461, which retains the single disulfide bond
and is as stable as the full myoc-OLF construct. The data presented here inform new testable hypotheses for interactions
with specific TEM components, and will assist in design of therapeutic agents for myocilin glaucoma.
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Introduction
Myocilin, the protein most closely associated with inherited
forms of open angle glaucoma (OAG) through genetic linkage
studies, is a ,57 kDa glycoprotein composed of a secretion signal
sequence, coiled-coil region, and a ,30 kDa olfactomedin (OLF)
domain (Figure 1), which harbors 90% of all reported pathogenic
lesions [1]. The molecular mechanisms that lead to glaucoma are
not well established but are of significant biomedical interest given
that glaucoma is a leading cause of blindness worldwide, and
early-onset myocilin glaucoma accounts for ,4% of glaucoma
cases, primarily afflicting children [1].
Wild-type (WT) myocilin is secreted from human trabecular
meshwork (HTM) cells to the trabecular meshwork extracellular
matrix (TEM) [2,3,4], the anatomical region believed to regulate
intraocular pressure [4,5]. By contrast, mutant myocilins aggregate
in the endoplasmic reticulum (ER), leading to cell death and a
malfunctioning matrix. The net result is an increase in intraocular
pressure and retina degeneration, a hallmark of glaucoma [6]. A
gain-of-toxic-function is thought to underlie the pathophysiology
of myocilin glaucoma [7,8]. Temperature-sensitive secretion of
some myocilin variants [9,10] indicates that when protein
production is slowed, some mutant proteins appear native-like
and competent for trafficking out of the cell and to the TEM. In
cell culture, the toxicity of mutant myocilins can be reduced by the
addition of certain chemical chaperones [11,12], and in vitro, the
compromised stability of mutant myoc-OLFs can be restored with
some of the same compounds [13].
In spite of the importance of myocilin in inherited glaucoma
pathogenesis, little is known about its normal biological function in
the TEM, especially the OLF (myoc-OLF) domain. Full-length
myocilin has been shown to bind to TEM proteins such as laminin
and the Hep II domain of fibronectin [14,15], as well as the
glycosaminoglycan (GAG) heparan sulfate, but these interactions
are localized to the coiled-coil region of myocilin, and not myoc-
OLF [16]. The normal biological roles of myocilin are further
complicated by reports of myocilin localized to the mitochondria of
HTM cells [2,17], calpain-II dependent cleavage prior to secretion
[18], as well as its expression in other ocular tissues including sclera,
ciliary body, iris, retina and optic nerve head [19]. Moreover,
beyond the eye, OLF domains are found in numerous multicellular
organisms, and more than half of reported OLF domains are found
in neural tissues. OLF domains are proposed to play roles in
neurogensis, neural crest formation, dorsal ventral patterning, cell-
cell adhesion, cell-cycle regulation, cell-cell signaling, tumorigenesis,
and have been implicated in psychiatric disorders [20]. The explicit
roles of myocilin in any of these tissues and processes, however, are
not clear due to a lack of functional assays.
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of myoc-OLF to gain insight into its function and structure. The
study was enabled by our recent development of a preparative in
vitro expression system in which myoc-OLF is closely fused to a
cleavable maltose binding protein (MBP) [13]. Our current work
places the OLF domain for the first time in the context of other
known proteins. The analysis of myoc-OLF described herein also
provides a biophysical basis for the development of a new
therapeutic avenue for glaucoma in the context of a protein
conformational disorder.
Results
pH stability profile of myoc-OLF
We investigatedthe pH stability profile of myoc-OLF to elucidate
any preferences of this domain as well as to gain insight into its
resilience under different pH environments, such as low pH, that
might be encountered under a known age-related TEM stressor,
oxidativestress[21].Forthebroad96-wellpHscreen(TableS1),we
used the MBP-OLF fusion protein and adapted the differential
scanning fluorimetry (DSF) technique used originally to assess
thermal stability differences between WT and glaucoma-causing
myoc-OLFvariants [13].The melting ofMBPis deconvolutedfrom
the melting of OLF by the addition of 50 mM maltose. The melting
curves of MBP and OLF are readily distinguished in the stability
assay throughout the pH range tested. MBP is stable from pH 4-
10.5 [22], OLF is not affected by the presence of maltose [13], and
Sypro Orange is not pH sensitive in the range 4-10 (not shown).
To cross-validate the results obtained using the MBP-OLF fusion
protein, we subsequently tested cleaved myoc-OLF in a subset of
stabilizing and destabilizing buffers (Table S1). There was no
difference in melting temperature (Tm) between the MBP-OLF and
cleaved myoc-OLF among the pHs tested (Table S1), reinforcing
theindependenceofthe domains inthefusion protein.Interestingly,
myoc-OLF is stable in 100 mM buffers corresponding to a range in
pH of 4.6 to 7.4, but specifically in sodium lactate, acetate, MES,
phosphate and Hepes (Table 1, Table S1). Bicine at pH 7.0 and
glycine at pH 8.2 were also stabilizing buffers, albeit within a more
limited pH range (Table 1, Table S1). By contrast, OLF was
destabilized in pH 4.0–4.6, as well as the full pH range tested of Bis-
Tris, Imidazole, Tris, and CHES buffers (Table 1, Table S1).
The concentration dependence of buffer stabilization or
destabilization was further investigated using acetate buffer
pH 4.6 or Tris buffer pH 7.5 as examples, respectively (Table
S1). Myoc-OLF is more stable in 10 mM Tris pH 7.5 compared
to 100 mM Tris pH 7.5. For Tris buffer, increasing the ionic
strength by the addition of NaCl partially restores stability,
suggesting that counterions may play a role in this buffer system.
Conversely, for acetate buffer pH 4.6, a further increase of 2uCi n
the Tm value for myoc-OLF is observed when 100 mM acetate
buffer pH 4.6 is used compared to 10 mM (Table S1), with no
additional effects due to the presence of NaCl (not shown).
Stability analysis in the presence of GAGs
Interestingly, the preferred buffers for myoc-OLF contain
sulfate and acetate functional groups that are reminiscent of
GAGs, whereas those that are destabilizing in an overlapping pH
range harbor aliphatic amines (Table 1). Thus, we sought to
evaluate the stability of myoc-OLF in the presence of individual
GAGs found in the TEM [23] at physiologically relevant
concentrations [24] (Table 2). Indeed, a modest (DTm=4.5uC)
stabilizing effect was observed for myoc-OLF in the presence of a
relatively low concentration (0.75 mg/ml) of heparan sulfate,
whereas a similar increase in stability for chondroitin sulfate and
hyaluronic acid were observed only at higher concentrations of
10 mg/ml, at the outer limit of the physiological range, suggesting
a weaker effect. The addition of dermatan sulfate did not change
the Tm value of myoc-OLF in the full range tested.
Conformational analysis of myoc-OLF at pH 4.6, 5.8, and
7.2
In order to detect structural changes across the stable pH
regime, we next compared the secondary structure of myoc-OLF
by conducting CD melts in stabilizing buffers of varying pH. We
measured the CD spectrum in 10 mM acetate buffer pH 4.6,
below the calculated [25] pI=,5 of myoc-OLF, at the lower end
of the stable range, as well as in 10 mM phosphate buffer pH 5.8
where OLF was the most stable in our assay (Table 1, Table S1),
and at the physiological pH 7.2 expected in the TEM under
normal conditions.
Table 1. Summary of stabilization of myoc-OLF by buffers of
varying pH.
Buffer pH range Stabilizing Buffer
a
Sodium Lactate/HCl 4.0–4.4 No
Sodium Lactate/HCl 4.8–5.2 Yes
Sodium Acetate/Acetic Acid 4.2 No
Sodium Acetate/Acetic Acid 4.6–6.2 Yes
MES/NaOH 5.0–7.4 Yes
Bis-Tris/HCl 5.2–8.0 No
Imidazole/HCl 5.4–8.2 No
K2HPO4/NaH2PO4 5.8–7.4 Yes
K2HPO4/NaH2PO4 7.8–8.6 No
Hepes/NaOH 6.0–7.2 Yes
Hepes/NaOH 7.6–8.4 No
Tris/HCl 6.6–8.6 No
Bicine/NaOH 7.0 Yes
Bicine/NaOH 7.2–8.6 No
CHES/NaOH* 8.0–8.8 No
Glycine/NaOH 8.2 Yes
Glycine/NaOH 8.6 No
aNo: Tm,51.7uC; Yes: Tm.51.7uC. The lower limit cutoff is 1uC less than the
originally reported Tm of myoc-OLF in phosphate buffer, using DSF [13]. Full
data are presented in Table S1.
doi:10.1371/journal.pone.0016347.t001
Figure 1. Multiple sequence alignment for myocilin and non-ocular ortholog amassin. Alignment includes myocilin from H. sapiens (gi
3065674), D. rerio (gi 62632725), B. taurus (gi 74356501), S. scrofa (gi 47522798), M. musculus (gi 15077142), R. norvegicus (gi 3845607), and amassin
from S. purpuratus (gi 28453877). The region shaded in grey contains the N-terminal signal sequence and coiled-coil region, whereas the OLF domain
remains unshaded. The consensus predicted secondary structures are shown in the last line (h, alpha-helix; e, beta-strand). Blue, similar residues; red,
conserved residues; asterisk, reported disease-causing mutation in human myocilin [49]. The alignment and predicted secondary structure were
generated using PROMALS [53]. Solid black boxes enclose peptides identified in both core-OLF and myoc-OLF by mass spectrometry; whereas
dashed boxes enclose peptides identified only in myoc-OLF (see text).
doi:10.1371/journal.pone.0016347.g001
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different pH values. The 200–210 nm range is more positive at
pH 4.6 than the others, suggestive of non-native features of OLF
in this buffer environment, but otherwise there are only slight
differences in the intensity of the two major minima at ,217 and
,230 nm (Figure 2A). Component spectra, identified using
singular value decomposition (SVD) analysis, reveal three
significant spectral contributions. By far the most predominant
component is one that contains both minima, followed by two
minor contributions from spectra that resemble random coils
(Figure 2B). Notably, there is no significant contribution from
features at 208 nm and/or another at 222 nm; thus, there is no
evidence of a-helices in myoc-OLF. The broad ,217 nm
minimum, which is characteristic of antiparallel b-sheets, resem-
bles the CD spectrum of a smaller OLF construct expressed in P.
pastoris [26], but the prominent shoulder near 230 nm has not
been seen previously. The lack of this latter feature in the P. pastoris
OLF construct may have been a result of its N-terminal truncation
or the use of Tris pH 8.0 [26], a destabilizing buffer (Table 1,
Table S1).
Consistent with the aggregation propensity observed in mutants
that lead to myocilin glaucoma, the unfolding transitions of myoc-
OLF are irreversible. Sample precipitation was seen under all
experimental conditions tested, including all concentrations, pH
and temperature ranges. Nevertheless, there is substantial evidence
for a highly cooperative transition [27]. First, at all three pH
values, a sharp transition and similar isodichroic point near
238 nm are observed for myoc-OLF (Figure 3). Second, the
differences in Tm for the melting curves monitored at the two local
minima are consistently within 1uC of each other, and within error
of the fit to the Tm obtained from the Boltzmann sigmoid
equation, which assumes a two-state model (Table S2). Third,
there is no obvious scan rate dependence of denaturation (not
shown), suggesting that the melting transition is under thermody-
namic, rather than kinetic control. Nevertheless, because we were
not able to find experimental conditions of reversibility for myoc-
OLF, the extent of the validity of thermodynamic parameters
obtained using a two-state model cannot be assessed. We note,
however, that thermodynamic parameters we obtained using this
assumption with excellent error statistics (Text S1, Figure S1,
Table S2) are similar to those of a-chymotrypsin [28], a protein
that exhibits both similar mass and CD spectrum as myoc-OLF
(see Discussion).
The transition to the denatured state for myoc-OLF at pH 4.6
occurs between 40–50uC (Figure 3A). Upon denaturation, the
ellipticity is reduced by 50% and there is a shift in minimum at
216 nm in the folded state to 220 nm in the denatured state. SVD
deconvolution (not shown) reveals a significant reduction in the b-
sheet component and an increase in the random coil component,
suggesting the precipitated sample is likely a molten globule with
local secondary structure. By comparison, for both unfolding
experiments conducted at pH 5.8 (Figure 3B) and pH 7.2
(Figure 3C), the transition occurs between 50 and 60uC with a
fourfold reduction in signal intensity between folded and unfolded
states of myoc-OLF. Less residual secondary structure remaining
in these higher pH experiments may be attributed to the difference
in net charge per residue. In conditions far from the pI of myoc-
OLF, such as at pH 7.2, secondary structure would be expected to
be disrupted due to the high net charge per residue. By contrast, at
pH 4.6, myoc-OLF is closest to its pI where it may experience less
repulsion and therefore retain secondary structure in the
denatured state [29].
The Tm of myoc-OLF at pH 4.6 is nearly 10uC lower than the
Tm at pH 5.8 or 7.2, and ,3uC lower than that measured by DSF
using the same ionic strength buffer (Table 1). Using a two-state
assumption (see caveats above), comparison of the free energy of
unfolding, as well as both enthalpy and entropy components, also
indicate a lower barrier to unfolding (Table S2). Nevertheless, even
the values at pH 4.6 are well within parameters obtained from
numerous other folded proteins [28]. The thermodynamic values
fit for myoc-OLF above its pI indicate a larger energy barrier and
more stable protein, consistent with the measured increase in Tm.
Finally, the unfolding transition at neutral pH was further
corroborated by a thermal melt in which intrinsic tryptophan
fluorescence was monitored at pH 7.2 (Figure 3D). Indeed, the
intrinsic Tm measured by both CD and Trp fluorescence melts is
close to the Tm=52.7uC we previously reported using the more
Figure 2. CD signatures of myoc-OLF domain at varying pH. (A) Prominent minima are observed at ,217 nm and ,230 nm for both
experimental spectra (solid) and reconstructed spectral fit from SVD analysis (dashed). (B) Top component spectra from SVD analysis. Inset: relative
contribution.
doi:10.1371/journal.pone.0016347.g002
Table 2. Stabilization of myoc-OLF by GAGs.
Tm (6C) DTm (6C)
None 52.460.1 0
Chondroitin Sulfate 57.760.0 5.3
Dermatan Sulfate 52.760.0 0.3
Heparan Sulfate
a 57.260.0 4.8
Hyaluronic Acid 55.460.1 3.0
aFor these experiments, heparan sulfate concentration was 0.75 mg/ml,
whereas all other GAGs were present at 10 mg/ml.
doi:10.1371/journal.pone.0016347.t002
Characterization of the Myocilin OLF Domain
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16347facile, if indirect, DSF technique [13]. The melting thermogram
overlays particularly well with the curve obtained monitoring
,230 nm by CD, suggesting tryptophan residues contribute to
this CD signal (see Discussion).
Limits of the myoc-OLF core domain
We subjected myoc-OLF to limited proteolysis to identify its
three dimensional core structure(s). In most constructs of myoc-
OLF studied in the laboratory, a disulfide bond is formed between
the only two available cysteine residues (Cys 245 and Cys 433)
[13,26], which are 189 residues apart. Yet, protein domains are
typically composed of ,150 amino acids [30]. It is possible that
the two cysteine residues, far apart in sequence, are nevertheless
topologically close. This could lead to either two or more smaller
structural domains or one larger than average single domain.
Overall, myoc-OLF is resistant to cleavage by proteases at room
temperature, including trypsin, a-chymotrypsin, pepsin, and V8
protease (not shown) suggesting that our construct consisting of
residues 228–504 of myocilin, comprises a well folded, ,30 kDa
protein. However, incubation with subtilisin A, a non-specific
protease that cleaves after large uncharged residues, generated a
smaller domain of ,25 kDa (Figure 4A). Similar results were
obtained with the likewise promiscuous protease papain (not
shown). The CD spectrum of core-OLF is similar to that of myoc-
OLF with some minor exceptions, a 202 nm shoulder character-
istic of a type I b-turn [31], and a more pronounced 230 nm
shoulder (Figure 4B). As seen previously with myoc-OLF [13], the
disulfide bond remains intact in core-OLF. Observed using the
thiol-sensitive fluorogenic reagent, ThioGlo (see Materials and
Methods), fluorescence increases only in samples in which the
disulfide bond in core-OLF has been reduced with tris(2-
carboxyethyl)phosphine (TCEP) (Table 3). Finally, the Tm is
unchanged, 53.460.2uC measured by DSF.
Peptide mass fingerprinting reveals that the N- and C-termini of
core-OLF are truncated compared to myoc-OLF (Figure 1,
Table 4). For core-OLF, the most N-terminal fragment observed
in the spectrum encompasses residues 238–258, the extreme C-
terminal peptide observed for core-OLF comprises residues 408–
422 (Table 4), whereas the peptides TLTIPFK (residues 462–468,
Figure 4C, Table 4) and YSSMIDYNPLEK (residues 473–484,
Figure 4D, Table 4) are absent. The truncated C-terminal 44
residues may form a structural element not detected by SDS-
PAGE due to its small size, or it may be largely unordered. In sum,
consistent with the ,25 kDa fragment size, and digest analysis, the
main structural domain of myoc-OLF harbors a disulfide bond
and is likely inclusive of residues Ser 238 and Lys 461.
Discussion
Functional significance
The human TEM, a microenvironment in the eye consisting of
fibrillar and curly collagens, elastic fibrils, basement membrane and
amorphous basement membrane-like materials, as well as other
specific proteins, proteoglycans and GAGs, is the anatomical region
that controls outflow of aqueous humor in the eye [23]. The
structural and functional details of this interconnected matrix, its
receptor-mediated interactions with HTM cells, and mechanisms
leading to phenotypes observed in the diseased state, are poorly
understood [1]. The proper functioning of this complex tissue
involves adaptation to a host of cellular and environmental stressors
over time, and cumulative long-term detrimental effects of oxidative
stress have been implicated in decreased aqueous humor outflow.
Eventually, poor flowcontrolleads to an impaired ability to regulate
eye pressure, and subsequently, glaucoma [21]. Changes in GAG
Figure 3. Thermal unfolding of myoc-OLF monitored by CD
spectropolarimetry. Melts were conducted at (A) pH 4.6 (B) pH 5.8
and (C) pH 7.2. For each, 11 spectra are overlayed in the region of
melting as well as two additional extrema. (D) Comparison of
tryptophan fluorescence melt with CD melts from above. Each curve
is normalized to the range of its respective signal.
doi:10.1371/journal.pone.0016347.g003
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samples [32,33], butthemechanismsthat bring about thesechanges
are unknown. In addition, the roles played by myocilin in the TEM,
either normal or pathogenic, are not clear. In this study, we have
unraveled some of the molecular characteristics of the myoc-OLF
domain in the context of its TEM microenvironment, which will aid
future functional characterization.
Several lines of evidence support the notion that GAGs provide
a favorable environment for myoc-OLF to function, even though
Figure 4. Analysis of core OLF domain. (A) SDS-PAGE analysis of myoc-OLF before and after limited proteolysis by subtilisin A. Lane 1, myoc-OLF,
Lane 2, core-OLF. Molecular mass markers denoted in kDa. (B) Overlay of core-OLF and myoc-OLF CD spectra at pH 7.2. (C, D) Comparison of trypsin
digest/MALDI TOF/TOF mass spectra of myoc-OLF (top) and core OLF domain (bottom) in two key regions (see text, Table 4).
doi:10.1371/journal.pone.0016347.g004
Table 3. Characterization of disulfide bond in core-OLF.
Sample Fluorescence Intensity (513 nm)
core-OLF (6 mM) 0.7
core-OLF (6 mM), TCEP (5 mM) 184.4
doi:10.1371/journal.pone.0016347.t003
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the myoc-OLF region from any organism. Four GAG attachment
sites to the myoc-OLF domain are predicted by the ELM database
[34] within residues 232–235, 237–240, 330–333 and 443–446,
suggesting that direct linkages are possible. The microenvironment
of myoc-OLF in the TEM is also replete with GAGs at a total
concentration of 1–2 mg/ml [35], with the approximate compo-
sition of 20–25% hyaluronic acid or hyaluronan, 40–60%
chondroitin and dermatan sulfates, 5–10% karatan sulfate, and
15–20% heparan sulfate [23]. Our experiments reveal a modest
increase in stability for myoc-OLF in the presence of heparan
sulfate, chondroitin sulfate, and hyaluronic acid. Although no
change in Tm was observed in the presence of dermatan sulfate, no
GAGs tested destabilized myoc-OLF. Interestingly, whereas direct
binding of chondroitin sulfate to another OLF-containing protein,
mouse photomedin, has been shown [36], the presence of
chondroitin sulfate only weakly influences thermal properties of
myoc-OLF. This result suggests that chondroitin sulfate may have
different functional significance for related OLF-containing
proteins.
By contrast, a more pronounced effect on myoc-OLF stability
was observed under physiologically relevant concentrations of
heparan sulfate. Even though direct binding to the OLF domain
has been ruled out by a previous study demonstrating binding via
the N-terminal coiled-coil domain of myocilin [16], the knowledge
that heparan sulfate binds to myocilin indicates that this GAG is in
the local milieu of myoc-OLF. The observation that heparan
sulfate thermally stabilizes myoc-OLF should prompt experiments
to further clarify the nature of the mechanism of stabilization.
In addition, although heparan sulfate appears to exert a modest
stabilizing effect on myoc-OLF in the absence of other analytes, it
seems plausible that cations might enhance the favorable specific
interactions between the negatively charged GAGs and the
negatively charged OLF domain under physiological conditions.
For example, detailed functional studies of amassin, a related, but
non-ocular, OLF-containing protein (Figure 1) from the inverte-
brate animal sea urchin, demonstrates the requirement of the
amassin OLF domain for cell-cell adhesion in coelomocytes. This
process also requires the presence of Ca
2+, and higher multimeric
states of the amassin OLF domain [37]. To date, however, no
canonical Ca
2+-binding sites have been identified in myoc-OLF,
and to the best of our knowledge, Ca
2+ has not been included in
any assays. In our hands, myoc-OLF does not bind Tb
3+,aC a
2+
mimic [38] (not shown), and has only been isolated as a monomer
by gel filtration [13]. Although it is possible that these two related
proteins have unique modes of interactions and binding partners,
based on our study we raise the possibility that certain key
components, such as GAGs and/or metal ions, may be missing
from functional assays of myocilin attempted to date.
Lastly, the importance of elucidating the mechanism by which
GAGs stabilize myoc-OLF is underscored by the finding that the
concentrations of GAGs in glaucomatous eyes deviate from those
of healthy eyes [32,33]. Specifically, concentrations of sulfated
GAGs, such as chondroitin sulfate, are higher in samples derived
from early-onset glaucoma patients than from controls [33], and
the concentration of hyaluronan decreases in adult-onset OAG
patient-derived specimens compared to controls [32]. Given the
connection between myocilin and early-onset glaucoma [39], an
understanding of the nuances of different GAG interactions with
myoc-OLF may pave the way to a better comprehension of
myocilin glaucoma pathogenesis.
Structural significance
Although predominantly b-sheet-containing proteins, such as
the immunoglobulins [40], exhibit a trough at ,217 nm that is
characteristic of antiparallel b-sheets [31], of particular interest is
the prominent ,230 nm shoulder that had not been observed
previously. One possibility is that a b-turn [41] is present, a
hypothesis supported by prediction of b-turns in myoc-OLF by
bioinformatics [42]. Alternatively, or in addition, the 230 nm
feature may arise from aromatic residues, as observed in certain
serine proteases. For example, a notable 230 nm band in a-
chymotrypsin has been attributed to a tryptophan residue whose
conformation is sensitive to changes in its environment upon
activation of a-chymotrypsinogen to a-chymotrypsin [43]. In
Table 4. Observed and calculated mass spectrum peaks for myoc-OLF and core-OLF.
Residue Range Calculated Mass Observed Mass DMass MS/MS Sequence
Core-OLF 267–272 827.3868 827.3786 20.0082 YGVWM
aR
288–296 975.5105 975.5100 20.0005 yes IDTVGTDVR
347–355 1096.5521 1096.5477 20.0044 yes YELNTETVK
273–287 1882.8970 1882.8944 20.0026 DPKPTYPYTQETTWR
406–422 2099.0403 2099.0400 20.0003 yes LNPENLELEQTWETNIR
238–258 2232.0601 2232.0674 0.0073 yes SGEGDTGC
bGELVWVGEPLTLR
Myoc-OLF 462–468 819.4974 819.5486 0.0512 TLTIPFK
267–272 843.3817 843.3954 0.0137 YGVWM
cR
288–296 975.5105 975.5311 0.0206 IDTVGTDVR
347–355 1096.5521 1096.5712 0.0191 YELNTETVK
473–484 1459.6672 1459.6852 0.0180 YSSMIDYNPLEK
273–287 1882.8970 1882.9452 0.0482 DPKPTYPYTQETTWR
406–422 2099.0403 2099.0972 0.0569 LNPENLELEQTWETNIR
297–314 2180.0369 2180.0801 0.0432 QVFEYDLISQFMQGYPSK
aA indicates oxidation of methionine,
bB designates carbamidomethyl cysteine,
cC indicates methionine sulphone.
doi:10.1371/journal.pone.0016347.t004
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overlays closely with that from 230 nm observed in CD
(Figure 3D). Of the seven Trp residues in myoc-OLF, two, Trp
270 and Trp 286, are in and near, respectively, a proline-rich
region. Alternatively, Trp 373 is within a region with significant
disorder probability as predicted by GlobPlot [44]. Future studies
involving systematic mutagenesis of each Trp residue may shed
more light on the properties of this unusual feature of the CD
spectrum.
Intriguingly, the CD spectrum of core-OLF is similar to that of
the bc-crystallin superfamily. Crystallins are cytoplasmic lens cell
proteins associated with genetic forms of cataract, a condition in
which the crystallins precipitate. Regardless of their quaternary
structure, which often exhibits functionally significant polydisperse,
domain-swapped oligomers [45], CD spectra of crystallins include
the same features at ,202 nm, ,217 nm, and ,230 nm as seen
with core-OLF [46], albeit with different relative intensities. Myoc-
OLF exhibits no significant sequence homology with crystallins, is
,10 kDa larger, is not known to oligomerize, nor observed to
harbor two structural domains [47]. Nevertheless, OLF likely shares
structural features such as similar length or twist of its b-strands,
and/or the unusually strained torsion angles in a b-hairpin. Further
characterization of the three-dimensional structure of an OLF
domain will help elucidate the extent of similarity of features with
thecrystallins,includingrepeat structuresinmyoc-OLFthat maybe
important for myocilin self assembly and/or function in the TEM,
or plausible molecular mechanisms for the severe aggregation
properties observed upon thermal unfolding.
Implications for new therapeutic directions
The details of the unfolding mechanisms of WT and disease-
causing myoc-OLF domains variants, particularly at physiological
pH, are informative for a pharmacological chaperone therapeutic
effort [48] for myocilin glaucoma. In this approach, the binding of
small molecules will enhance the stability of the mutant myocilins
to WT levels so that after folding in the ER, mutant myocilins will
meet quality control requirements and be competent for secretion
to the TEM.
Both thermodynamics and kinetics may be important in
chaperone therapy for myocilin glaucoma. The therapeutic small
molecule might bind to a folded mutant protein to restore its
stability to that of WT, and/or bind to a non-native conformation
and accelerate folding to the native state. From this study we know
that the ,31 kDa WT myoc-OLF domain is a stable entity that
appears to unfold under thermodynamic control in a highly
cooperative transition. We can now move forward to compare
unfolding pathways of the numerous missense mutants of OLF. If
mutant OLFs unfold in similarly cooperative transitions, thermal
stabilization of the fully folded protein may be sufficient for
preventing aggregation and improving secretion, and screening for
candidate chaperone molecules would be based on thermal stability
alone. However, a more likely scenario is that deviations from two-
state unfolding exist for at least some of the reported mutants [49].
In this case, a pharmacological chaperone may need to be tailored
in such a way that it alters the folding pathway back to a fully
cooperative mechanism observed in WT myoc-OLF. Future studies
will examine to what extent such unfolding intermediates exist for
specific glaucoma-causing myoc-OLF mutants.
Materials and Methods
Expression and purification of myoc-OLF
The myoc-OLF gene was introduced into the MBP fusion
vector, pMAL-c4x, as described previously [13]. Expression and
purification of MBP-OLF followed previously described proce-
dures, as did generation of cleaved myoc-OLF by incubation with
Factor Xa and further purification [13]. SDS-PAGE analysis was
conducted as described [50].
Thermal stability assay for buffer and pH analysis
Our fluorescence thermal stability assay [13] utilizing DSF [51]
was adapted to identify buffer and pH preferences for myoc-OLF.
Reactions of 30 mL were prepared at room temperature and
delivered to 96-well optical plates (Applied Biosystems) before
sealing with optical film (Applied Biosystems). The reaction
mixture consisted of 1 mM myoc-OLF or MBP-OLF in 10 mM
sodium phosphate dibasic/potassium phosphate monobasic,
200 mM NaCl pH 7.2 (Buffer A) and 5X Sypro Orange
(Invitrogen). Buffers from pH 4 to pH 9 were obtained from the
pHat
TM Buffer screen (Emerald Biosciences) and added to each
reaction at a final concentration of 100 mM, with the exception of
N-Cyclohexyl-2-aminoethanesulfonic acid (CHES), which had a
final concentration of 50 mM. Only for the initial screen was
MBP-OLF used and 50 mM maltose added to the reaction
mixture. Selected DSF measurements were repeated with cleaved
myoc-OLF in acetate, MES, phosphate, Tris, bicine, and glycine
buffers. Fluorescence data were acquired on an Applied
Biosciences Step-One Plus RT-PCR instrument equipped with a
fixed excitation wavelength (480 nm) and a ROX emission filter
(610 nm). Melts were conducted from 25–95uC with a 1uC per
min increase. Collected data were baseline subtracted, trimmed to
include both the boundaries and the transition of interest, and
subjected to Boltzmann sigmoid analysis (see below).
Thermal stability assay in the presence of GAGs
The thermal stability assay described above was employed to
test for increased myoc-OLF stability in the presence of GAGs
including chondroitin sulfate (shark cartilage, Sigma), dermatan
sulfate (TCI America), heparan sulfate (bovine kidney, Sigma), and
hyaluronic acid (rooster comb, Sigma) at concentrations ranging
from 0 mg/ml to 10 mg/ml. Samples were prepared in 10 mM
Tris, pH 7.5 and 200 mM NaCl, diluted from a 5x stock solution.
GAGs were added from 20 mg/ml stock solutions in water,
keeping protein and Sypro Orange concentration the same as
above. Data analysis was performed as described above.
Circular dichroism (CD) spectropolarimetry
CD was performed on a Jasco J-810 spectropolarimeter with
purified myoc-OLF (8–10 mM) prepared in Buffer A, Buffer A
adjusted to pH 5.8, as well as in 10 mM sodium acetate/acetic
acid and 200 mM NaCl, pH 4.6. Melts were performed in
triplicate on each of the samples by raising the temperature from 5
to 90uCi n1 uC /min increments using a Neslab RTE-111
(Thermo Scientific) circulating water bath and monitoring the
profiles between 200 and 300 nm in a 0.1 cm cuvette. Ten
spectra, scanned from 300 to 200 nm at rate of 500 nmNmin
21,
were then averaged at the designated temperature. Our attempts
to acquire reliable data below 200 nm were not successful due to
voltage limits of the instrument and available nitrogen flow rate.
Temperature increase and spectra acquisition lasted about five
minutes per degree Celsius, and no differences in melting
transitions were observed when the scan rate was reduced to
0.5uC /min (data not shown). In all cases, samples precipitated
after melting, including reversibility tests in which the temperature
was raised just to the Tm and then cooled (not shown).
Each averaged spectrum was background-corrected and
converted to mean residue ellipticity
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where Mres=112.9 is the mean residue mass calculated from the
protein sequence;hobsisthe observed ellipticity (degrees)atwavelength
l; d is the pathlength (cm); and c is the protein concentration (g/ml).
CD melt data from 205 – 300 nm were deconvoluted into component
spectra using the singular value decomposition procedure in Matlab
(The Mathworks), and their statistical significance was calculated
based on singular values. The top three components comprising
$95% of the CD signal were then selected for reconstitution for the
final fit plotted in Figure 2. Inspection of difference spectra confirmed
that additional components consist of noise.
Tryptophan fluorescence spectroscopy
Measurements were carried out in triplicate on a FluoroMax-3
spectrofluorimeter (Horiba Scientific). Intrinsic tryptophan fluores-
cence of myoc-OLF (2 mM) in Buffer A was excited at 280 nm (slit
width 1 nm) and emission recorded in the range 300–400 nm (slit
width 5 nm) with a maximum at 340 nm corresponding to tryptophan
fluorescence emission. Each sample was heated from 20 to 70uCo r4 5
to 65uC, with a rate of three minutes per degree Celsius, using a Neslab
RTE-7 Digital Plus (Thermo Scientific) circulating water bath.
Boltzmann sigmoid analysis
The baseline-subtracted and trimmed melt curves acquired by
the fluorescence thermal stability assay, CD, and intrinsic
fluorescence were processed using GraphPad Prism. The reported
Tm is the inflection point of the sigmoidal curve, and is calculated
using the Boltzmann sigmoid equation
Y~
LLz UL{LL ðÞ
1zexp Tm{X ðÞ =Slope ðÞ
where UL and LL are the values of minimum and maximum
intensities, respectively [51].
Limited proteolysis
Myoc-OLF was pre-screened at room temperature against a
variety of proteases including trypsin, a-chymotrypsin, pepsin,
papain, V8 protease and subtilisin A to identify a protease and
concentration capable of producing a discrete smaller construct
detectablebySDS-PAGE.Theoptimalreactionconditionconsisted
of a 1:200 dilution of subtilisin A (Sigma Aldrich, 1 mg/ml) in
0.2 mg/ml myoc-OLF in 10 mM Hepes pH 7.5 or 1:200 dilution
of papain (Sigma, 1 mg/ml) in 0.2 mg/ml myoc-OLF in 10 mM
MES pH 6.2. The reaction was incubated at room temperature for
30 minutes followed bysubsequent quenching byeitherthe addition
of Complete Protease Inhibitor Cocktail (Roche) or SDS-PAGE
sample loading buffer for SDS-PAGE analysis and in-gel digestion
for mass spectrometry analysis. The core OLF product was
fractionated from smaller digestion products on a Superdex 75
GL column (GE Healthcare) equilibrated with Buffer A. The core-
OLF sample was further analyzed by CD as described above.
Disulfide bond formation was confirmed with ThioGlo (EMD
Biosciences) and the Tm measured as described [13].
In-gel digestion and MALDI-TOF/TOF MS analysis
In-gel digestion of myoc-OLF and core-OLF was carried out as
described previously [52]. Digested and dried samples were
subjected to peptide mass fingerprinting analysis using the Georgia
Institute of Technology Bioanalytical Mass Spectrometry Facility.
Spectra were acquired on an Applied Biosystems 4700 Proteomics
Analyzer MALDI-TOF/TOF tandem mass spectrometer. Core-
OLF was also analyzed by MS/MS. Peaks were analyzed by using
MASCOT (GPS Explorer, Applied Biosystems). Only identified
peptide fragments with a.3:1 signal-to-noise intensity were
included in analysis. Samples were analyzed in duplicate. Due to
the nonspecific nature of subtilisin cleavage, N-/C-terminal
sequencing was not undertaken.
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Figure S1 Melt data fit to a two-state transition. Melt
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